ÂÜÀòÂÒÂ×

Daniel P. Van Kammen, MD, PhD has held successful leadership positions in CNS Clinical Development of large Pharma, such as Johnson & Johnson and Aventis/Sanofi (where he was head of CNS Phase 1-2), and Biotechs such as ACADIA as VP of Clinical Development and CHDI Foundation where he was responsible as CMO for building the clinical development infra-structure and collaborating with Biotechs for 15 years. His expertise is in clinical development of neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s disease, and chronic mental illness such as schizophrenia.

Prior to his career in the pharmaceutical Industry he was an internationally recognized Academic schizophrenia researcher and Key Opinion Leader at the NIMH and as professor at the University of Pittsburgh, where he headed biological/biomarker, pharmacological and cognitive research programs in schizophrenia. In addition, Dr. Van Kammen was on the Adjunct Faculty of UPENN and Columbia University and is presently an independent CNS Drug Development consultant for a number of Pharma, Biotechs and Venture Capitalist firms, and member of several Administrative and Scientific Advisory Boards. Dr. Van Kammen obtained his MD and PhD at the University of Utrecht, Utrecht, the Netherlands, and completed his Psychiatric training at the Johns Hopkins Hospital, Baltimore, MD. He is Board certified in Psychiatry.